A Phase 2 Multicenter Evaluation of the Safety and Efficacy of TOCOSOL(TM) Paclitaxel (S-8184 Paclitaxel Injectable Emulsion) in Patients With Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma of the Urothelium

NCT00077688 Phase 2 COMPLETED

Phase 2B, multicenter study evaluating the safety and efficacy of weekly TOCOSOL Paclitaxel in taxane-naive patients receiving second line chemotherapy for metastatic or locally advanced, unresectable transitional cell carcinoma of the urothelium

Details

Lead sponsor	Achieve Life Sciences
Phase	Phase 2
Status	COMPLETED
Enrolment	44
Start date	2003-11
Completion	2007-09

Conditions

• Bladder Neoplasms
• Ureteral Neoplasms
• Urethral Neoplasms
• Carcinoma, Transitional Cell

Interventions

• TOCOSOL Paclitaxel

Primary outcomes

• Objective response rate

Countries

United States